Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metropolis HealthcareNSE:METROPOLIS -0.47%93 PEG Ratio is 19.86 as of Aug. 02, 2026, which is 171% above its 10-year median of 7.34. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 93/100 and a GF Value™ of ₹600.08 (Fairly Valued). The stock has 4 warning signs investors should review. Among 36 Medical Diagnostics & Research companies, Metropolis Healthcare ranks worse than 94.44% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Metropolis Healthcare's PEG Ratio or its related term are showing as below:
NSE:METROPOLIS'
s PEG Ratio Range Over the Past 10 Years
Min: 1.91 Med: 7.34 Max: 48.11
Current: 19.75
During the past 11 years, Metropolis Healthcare's highest PEG Ratio was 48.11. The lowest was 1.91. And the median was 7.34.
NSE:METROPOLIS's PEG Ratio is ranked worse than 94.44% of 36
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.485
vs NSE:METROPOLIS: 19.75
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Metropolis Healthcare (NSE:METROPOLIS) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:METROPOLIS vs TMO, DHR, IDXX: PEG Ratio Comparison
For the Diagnostics & Research subindustry, Metropolis Healthcare's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metropolis Healthcare PEG Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Metropolis Healthcare's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Metropolis Healthcare (NSE:METROPOLIS) has a PEG Ratio of 19.86 as of Aug. 02, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Metropolis Healthcare and its competitors. This is 171% above median its historical median of 7.34. Over the past decade, Metropolis Healthcare's PEG Ratio has ranged from 1.91 to 48.11. According to the industry distribution chart, Metropolis Healthcare ranks #34 out of 36 companies in the Medical Diagnostics & Research industry, placing it in the top 94.4%.
Is Metropolis Healthcare's PEG Ratio too high?
Metropolis Healthcare's current PEG Ratio of 19.86 is 171% above median its 10-year median of 7.34. Over the past 10 years, this metric has ranged from a low of 1.91 to a high of 48.11. The Medical Diagnostics & Research industry median PEG Ratio is 2.49. Metropolis Healthcare's value of 19.86 is 699.2% above this industry median. Based on the distribution chart, Metropolis Healthcare ranks #34 out of 36 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Metropolis Healthcare has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's PEG Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Metropolis Healthcare ranks #34 out of 36 companies for PEG Ratio. This places Metropolis Healthcare in the lower half of its industry. The industry median PEG Ratio is 2.49. Metropolis Healthcare's value of 19.86 is 699.2% above this benchmark. Historically, Metropolis Healthcare's own PEG Ratio has ranged from 1.91 to 48.11 over the past decade. While the company's 10-year median is 7.34 vs. the industry median of 2.49, Metropolis Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Diagnostics & Research company?
The median PEG Ratio among Medical Diagnostics & Research companies is 2.49, based on 36 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metropolis Healthcare's current PEG Ratio of 19.86 is 699.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Metropolis Healthcare and its competitors. For the Medical Diagnostics & Research industry, the median PEG Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metropolis Healthcare's current PEG Ratio is 19.86, which is 171% above median its own 10-year median of 7.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹600.08, compared to a current price of ₹582.45 — trading 2.9% below its estimated fair value. The current PEG Ratio is 19.86, which is 171% above median its 10-year median of 7.34 and 699.2% above the Medical Diagnostics & Research industry median of 2.49. Metropolis Healthcare's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current PEG Ratio is 19.86 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?
Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued.
The current stock price of ₹582.45 is trading 2.9% below its estimated GF Value™ of ₹600.08.
GuruFocus considers Metropolis Healthcare to be Fairly Valued.
Key valuation signals for NSE:METROPOLIS:
PEG Ratio: 19.86 (171% above median its 10-year median of 7.34)
GF Value™: ₹600.08 vs. price of ₹582.45 (2.9% below fair value)
Industry Position: 699.2% above the Medical Diagnostics & Research median (#34 of 36)
No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
93GF Score
Get the complete analysis for NSE:METROPOLIS
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:METROPOLIS has been successfully added to your 
